<DOC>
	<DOCNO>NCT00572611</DOCNO>
	<brief_summary>The primary objective study define absorption excretion kinetics bilastine man follow oral administration , investigate nature metabolites present plasma excreta . The secondary objective study assess safety tolerability bilastine</brief_summary>
	<brief_title>Human Mass Balance Study With Bilastine</brief_title>
	<detailed_description>Primary Endpoints : Whole blood plasma concentration total radioactivity parent drug . Urine faecal recovery total radioactivity . Characterisation identification metabolite plasma , urine faeces .</detailed_description>
	<criteria>No clinically important abnormal physical finding . No clinically significant abnormality result laboratory evaluation . Normal ECG . Normal supine blood pressure heart rate . Body weight 50 100 kg body mass index 18 30 kg/m2 . Able communicate well investigator comply requirement entire study . Provision write informed consent participate . Subjects must agree use adequate method contraception study 12 week dose . Subjects must negative urine screen drug abuse . Subjects must regular bowel habit . Administration IMP within 12 week entry study . Use prescribed medication St John 's Wort within 14 day OTC medication within 5 day dose . Existence surgical medical condition , judgement investigator , might interfere absorption , distribution , metabolism excretion IMP . History drug alcohol abuse past 2 year , alcohol consumption great 21 unit per week . Presence history allergy require treatment . Hayfever allow unless active require treatment within previous 2 month . Donation loss great 400 mL blood within 12 week entry study . Serious adverse reaction serious hypersensitivity drug . Presence hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV Ab ) HIV 1 HIV 2 antibody screen . Administration radiolabelled substance exposure significant radiation ( eg serial xray CT scan , barium meal etc ) within past 12 month . Any ECG abnormality screening ( include QTc interval &gt; 430 m ) . Past medical history clinically significant ECG abnormality , family history prolong QT interval syndrome . Abnormal diet substantial change eat habit within 30 day prior study initiation . Treatment known enzyme alter agent ( barbiturate , phenothiazine , cimetidine , etc . ) within 2 month prior study .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Mass Balance</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Absorption</keyword>
	<keyword>Excretion</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>